AIM
AIM ImmunoTech Inc.
$0.34
-39.66%
2026-05-08
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
Key Fundamentals
Forward P/E
-0.25
EPS (TTM)
$-8.62
Revenue Growth (YoY)
-53.3%
Profit Margin
0.0%
Beta
1.24
Market Cap
$3.0M
Avg Volume (10D)
976K
Recent Breakout Signals
No recent breakout signals detected for AIM.
Recent Price Range (60 Days)
60D High
$1.62
60D Low
$0.33
Avg Volume
3.7M
Latest Close
$0.34
Get breakout alerts for AIM
Sign up for Breakout Scanner to receive daily notifications when AIM triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
AIM ImmunoTech Inc. (AIM) is listed on the New York Stock Exchange (NYSE). Breakout Scanner monitors AIM daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. AIM operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.